Author/Authors :
Farhangi، H نويسنده Department of Pediatric Hematology and Oncology, Dr Sheikh Pediatric Hospital, Mashhad University of Medical Sciences (MUMS), Mashhad, Iran , , Ghasemi، A نويسنده Department of Pediatric Hematology and Oncology, Dr Sheikh Pediatric Hospital, Mashhad University of Medical Sciences (MUMS), Mashhad, Iran , , Banihashem، A نويسنده Department of Pediatric Hematology and Oncology, Dr Sheikh Pediatric Hospital, Mashhad University of Medical Sciences (MUMS), Mashhad, Iran , , Badiei، Z نويسنده Department of Pediatric Hematology and Oncology, Dr Sheikh Pediatric Hospital, Mashhad University of Medical Sciences (MUMS), Mashhad, Iran , , Jarahi، L نويسنده Department of Community Medicine, Mashhad University of Medical Sciences, Mashhad, Iran , , Eslami، G نويسنده Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics, College of Pharmacy, University of Florida, USA , , Langaee، T نويسنده Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics, College of Pharmacy, University of Florida, USA ,
Abstract :
Abstract
Background
Immune thrombocytopenic purpura (ITP)
is the most prevalent cause of
thrombocytopenia in children. Despite the
importance of ITP in children under 2-
years old, only a few publications are
available in the literature.ITP usually
presents itself as isolated
thrombocytopenia and mucocutaneous
bleeding.
Materials and Methods
This study was conducted on 187 under 2-
year-old children diagnosed with ITP and
treated at Dr. Sheikh Hospital from 2004
to 2011.In this retrospective study, clinical
symptoms, laboratory findings, history of
viral infections, vaccination history, and
treatment efficacy in children under 2-
years old with ITP were
investigated.Patients were followed for
one year after being discharged from the
hospital.
Results
The risk of the disease developing into
chronic form was higher in older children
(0.001). ITP in children under 3-months
old was significantly associated with
vaccination (p=0.007). There was no
significant differences between male and
female patients in regards to newly
diagnosed ITP, persistent, and chronic
disease status (p = 0.21). No significant
difference in bleeding symptoms was
observed between patients under 3-months
old and 3 to 24-months old (p=0.18).
Conclusion
Infantile ITP respond favorably to
treatment. The risk of the disease
developing into chronic form is higher in
3-to-24-month-old children compared to
under-three-month olds.
